Form 4: Acadia Pharmaceuticals Executive Brendan Teehan Reports Stock Transactions

EVP, COO, and Head of Commercial Brendan Teehan reports acquisition and disposal of Acadia Pharmaceuticals stock and stock options.

Summary

• Brendan Teehan, EVP, COO, and Head of Commercial at Acadia Pharmaceuticals, filed a Form 4 detailing changes in beneficial ownership.
• On March 25, 2024, Teehan acquired 10,048 shares of common stock upon vesting of performance stock units at a price of $0.
• Also on March 25, 2024, Teehan acquired 89,516 stock options with an exercise price of $17.84, vesting incrementally starting March 25, 2025, and expiring on March 24, 2034.
• Additionally, on March 25, 2024, Teehan acquired 27,460 restricted stock units, vesting in equal annual installments beginning March 25, 2025.
• On March 27, 2024, Teehan disposed of 5,140 shares of common stock at a price of $17.9 per share to cover withholding taxes related to the vesting of performance stock units.
• Following these transactions, Teehan beneficially owns 36,340 shares of common stock and 89,516 stock options.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The filing reflects standard executive compensation practices and tax-related sales, without indicating any significant positive or negative developments.

Positives

• The acquisition of stock options and restricted stock units suggests a long-term incentive for the executive to perform well.

Negatives

• The sale of shares to cover tax obligations, while routine, slightly reduces the executive's direct stake in the company.

Industry Context

Form 4 filings are standard practice and provide transparency into the trading activities of company insiders, allowing investors to gauge management's sentiment and alignment with shareholder interests. These filings are common across all publicly traded companies and are a regular part of market surveillance.

Comparison to Industry Standards

• Executive compensation packages often include stock options and restricted stock units to align management's interests with those of shareholders, similar to practices at companies like Biogen, Amgen, and Gilead Sciences.
• The vesting schedules for stock options and restricted stock units are typical, often spanning several years to incentivize long-term performance, which is consistent with industry norms.

Stakeholder Impact

• The transactions provide transparency to shareholders regarding executive compensation and stock ownership.
• The vesting of stock options and restricted stock units incentivizes the executive to contribute to the company's long-term success, potentially benefiting all stakeholders.

Key Dates